Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Sumant Ramachandra Purchases 200,000 Shares

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Sumant Ramachandra acquired 200,000 shares of the firm’s stock in a transaction dated Friday, March 21st. The stock was bought at an average price of $0.58 per share, for a total transaction of $116,000.00. Following the acquisition, the director now owns 200,000 shares of the company’s stock, valued at approximately $116,000. This trade represents a ? increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Lyell Immunopharma Stock Up 6.4 %

NASDAQ:LYEL opened at $0.59 on Friday. The firm has a market capitalization of $175.25 million, a P/E ratio of -0.75 and a beta of -0.41. The company has a fifty day moving average of $0.61 and a 200 day moving average of $0.87. Lyell Immunopharma, Inc. has a 52 week low of $0.48 and a 52 week high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The firm had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. As a group, analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target on shares of Lyell Immunopharma in a research note on Thursday, March 13th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Barclays PLC increased its stake in shares of Lyell Immunopharma by 7.4% during the fourth quarter. Barclays PLC now owns 258,380 shares of the company’s stock valued at $165,000 after buying an additional 17,765 shares during the period. Wells Fargo & Company MN boosted its holdings in Lyell Immunopharma by 27.8% in the fourth quarter. Wells Fargo & Company MN now owns 94,320 shares of the company’s stock valued at $60,000 after acquiring an additional 20,542 shares in the last quarter. Centiva Capital LP purchased a new position in Lyell Immunopharma during the 3rd quarter valued at $31,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Lyell Immunopharma by 13.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 308,551 shares of the company’s stock worth $197,000 after purchasing an additional 36,555 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in shares of Lyell Immunopharma in the 3rd quarter worth about $52,000. Institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.